Extended Data Fig. 5: Kaplan-Meier curves of overall survival of KRASG12-mutated, KRASG13-mutated and KRASWT patients in the placebo arm of the RECOURSE trial. | Nature Medicine

Extended Data Fig. 5: Kaplan-Meier curves of overall survival of KRASG12-mutated, KRASG13-mutated and KRASWT patients in the placebo arm of the RECOURSE trial.

From: Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Extended Data Fig. 5: Kaplan-Meier curves of overall survival of KRASG12-mutated, KRASG13-mutated and KRASWT patients in the placebo arm of the RECOURSE trial.The alternative text for this image may have been generated using AI.

Censoring events are indicated by vertical bars on the corresponding curve. Dotted lines and corresponding annotation indicate the median overall survival. The table underneath the plot denotes the numbers at risk. Cox regression-based hazard ratio (HR), 95% confidence interval (CI) and two-sided Wald test-based P values are plotted for pairwise comparisons.

Back to article page